STAT+: Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate

WASHINGTON — It has all the makings of a bombastic drug pricing debate: a highly anticipated drug, widespread press attention, a huge potential patient population, and a price higher than even some of the highest Wall Street estimates.

But when Biogen announced Monday it would charge $56,000 for an annual course of its just-approved Alzheimer’s treatment, the activists who are normally eager to criticize pharma and its pricing strategies were largely silent. So, too, were progressives on Capitol Hill, many of whom who’ve decried high drug prices as a key campaign issue.

Continue to STAT+ to read the full story…

STAT+: Despite its high price tag, the new Alzheimer’s drug isn’t reigniting the drug pricing debate

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top